Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (4): 26-36.doi: 10.6040/j.issn.1671-7554.0.2022.0913

• 临床医学 • Previous Articles    

Association of NAMPT with pathological features and immune infiltration of hepatocellular carcinoma using database information

CHANG Qing, LIU Jia, QU Ailin, YANG Yongmei   

  1. 1. Department of Clinical Laboratory;
    2. Center for Basic Medical Research, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2023-04-11

PDF (PC)

680

Abstract: Objective To analyze the expression profile of nicotinamide phosphoribosyltransferase(NAMPT)in hepatocellular carcinoma(HCC), and to explore the relationship between NAMPT expression and immune infiltration and clinicopathological features. Methods The expression profile of NAMPT in HCC was obtained from TIMER database. Based on UALCAN database, the correlation between NAMPT and alpha fetal protein(AFP)level was analyzed. Hepatocellular carcinoma transcriptome RNA-seq dataset was downloaded from TCGA-LIHC, and the mRNA expressions of NAMPT and immune-related molecules were extracted. The number of immune components, matrix components and the abundance of immune cell infiltration and the differences in the expression of immune-related molecules between high-NAMPT and low-NAMPT groups were evaluated using the estimation algorithm and the single sample gene set enrichment analysis(ssGSEA), respectively. Differences of above variables were compared. The relevance between NAMPT and immune cell infiltration was analyzed. Results TIMER database showed that the expression of NAMPT in HCC was lower than that in adjacent tissues(P<0.05). UALCAN database revealed that there was a negative low correlation between NAMPT expression and serum AFP level (r=-0.464, P<0.05). There were significant differences in stromal cell proportion, immune cell proportion and tumor cell purity(P<0.05)between high-NAMPT and low-NAMPT groups. ssGSEA analysis identified the infiltration levels of 20 immune cells were higher in the high-NAMPT group(P<0.05). The expressions of immune-related genes including NKG2D, CD40, FAS, ELANE,PDL1 and PDL2 were significantly different between the two groups(P<0.05). TIMER database showed NAMPT had a low positive correlation with macrophages(r=0.125, P=0.021), neutrophils(r=0.284, P<0.001), and dendritic cells(r=0.131, P=0.016), but a low negative correlation with tumor purity(r=-0.137, P=0.011). Conclusion NAMPT expression is correlated with clinicopathological features, and can reflect the status of immune microenvironment in HCC patients. Our study may provide a new clue for identifying the beneficiaries of HCC immunotherapy.

Key words: Nicotinamide phosphoribosyltransferase, Hepatocellular carcinoma, Bioinformatics, Immune infiltration, Tumor immune microenvironment

CLC Number: 

  • R574
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153(3): 812-826.
[3] Vogel A, Cervantes A, Chau I, et al. Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4(2018)v238-iv255] [J]. Ann Oncol, 2022, 33(6): 666.
[4] Zhao J, Zhu XC, Wu XS, et al. Identification of miR-4644 as a suitable endogenous normalizer for circulating miRNA quantification in hepatocellular carcinoma[J]. J Cancer, 2020, 11(23): 7032-7044.
[5] Hao X, Sun G, Zhang Y, et al. Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges[J]. Front Cell Dev Biol, 2021, 9: 775462. doi: 10.3389/fcell.2021.775462.
[6] Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020, 37(4): 443-455.
[7] Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
[8] Moore AM, Zhou L, Cui J, et al. NAD(+)depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition[J]. Proc Natl Acad Sci USA, 2021, 118(8): e2012469118. doi: 10.1073/pnas.2012469118.
[9] Gasparrini M, Audrito V. NAMPT: a critical driver and therapeutic target for cancer[J]. Int J Biochem Cell Biol, 2022, 145: 106189. doi:10.1016/j.biocel.2022.103189.
[10] Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, et al. NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through sirt1 and PARP[J]. Clin Cancer Res, 2018, 24(5): 1202-1215.
[11] Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, et al. NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis[J]. Oncotarget, 2017, 8(59): 99514-99530.
[12] Franceschini N, Oosting J, Tamsma M, et al. Targeting the NAD salvage synthesis pathway as a novel therapeutic strategy for osteosarcomas with low NAPRT expression[J]. Int J Mol Sci, 2021, 22(12): 6273. doi: 10.3390/ijms22126273.
[13] Zhang H, Zhang N, Liu Y, et al. Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer[J]. Cancer Res, 2019, 79(13): 3347-3359.
[14] Audrito V, Managò A, Gaudino F, et al. NAD-biosynthetic and consuming enzymes as central players of metabolic regulation of innate and adaptive immune responses in cancer[J]. Front Immunol, 2019, 10: 1720. doi: 10.3389/fimmu.2019.01720.
[15] Guo HJ, Li HY, Chen ZH, et al. NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis[J]. Oncol Lett, 2021, 21(5):390.
[16] Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[17] Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: An update to the integrated cancer data analysis platform[J]. Neoplasia, 2022, 25: 18-27. doi: 10.1016/j.neo.2022.01.001.
[18] Hilmi M, Vienot A, Rousseau B, et al. Immune therapy for liver cancers[J]. Cancers(Basel), 2019, 12(1): 77.
[19] Xing M, Wang X, Kiken RA, et al. Immunodiagnostic Biomarkers for hepatocellular carcinoma(HCC): the first step in detection and treatment[J]. Int J Mol Sci, 2021, 22(11): 6139. doi:10.3390/ijms22116139.
[20] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III Trial[J]. J Clin Oncol, 2020, 38(3): 193-202.
[21] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[22] Chowdhry S, Zanca C, Rajkumar U, et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling[J]. Nature, 2019, 569(7757): 570-575.
[23] Chen H, Wang S, Zhang H, et al. Nicotinamide phosphoribosyltransferase(Nampt)in carcinogenesis: new clinical opportunities[J]. Expert Rev Anticancer Ther, 2016, 16(8): 827-838.
[24] Adya R, Tan BK, Chen J, et al. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation[J]. Diabetes Care, 2008, 31(4): 758-760.
[25] Ma R, Wu Y, Zhai Y, et al. Exogenous pyruvate represses histone gene expression and inhibits cancer cell proliferation via the NAMPT-NAD+-SIRT1 pathway[J]. Nucleic Acids Res, 2019, 47(21): 11132-11150.
[26] Guo X, Tan S, Wang T, et al. NAD(+)salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity[J]. Hepatology, 2022. doi: 10.1002/hep.32658.
[27] Deng Y, Song Z, Huang L, et al. Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer[J]. Aging(Albany NY), 2021, 13(22): 24768-24785.
[28] Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2): 342-351.
[29] Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes[J]. Clin Cancer Res, 2017, 23(22): 6764-6770.
[30] Park H, Jung JH, Jung MK, et al. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma[J]. Hepatol Int, 2020, 14(2): 249-258.
[31] Korniotis S, Saichi M, Trichot C, et al. GM-CSF-activated human dendritic cells promote Tfh1 cell polarization in a CD40-dependent manner[J]. J Cell Sci, 2022, 135(21): jcs260298. doi: 10.1242/jcs.260298.
[32] Wang Y, Wang F, Wang L, et al. NAD(+)supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells[J]. Cell Rep, 2021, 36(6): 109516. doi: 10.1016/j.celrep.2021.109516.
[33] Lv H, Lv G, Chen C, et al. NAD(+)metabolism maintains inducible PD-L1 expression to drive tumor immune evasion[J]. Cell Metab, 2021, 33(1): 110-127.
[34] Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
[1] YU De-Xin, CAEI Ti-Gong, MA Xiang-Xing, ZHANG Xiao-Ming, LI Chuan-Fu. Angiogenesis and maturation of hepatocellular carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 51-54.
[2] LIU Teng, MA Yingchun. Expression of ECT2 in uterine corpus endometrial carcinoma and its clinical significance based on bioinformatics database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 63-71.
[3] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[4] ZUO Liping, JIANG Fengyang, ZHOU Binbin, FAN Jinlei, LIANG Yongfeng, DENG Zhanhao, YU Dexin. Value of preoperative multiphase MRI for predicting microvascular invasion and early recurrence of 169 hepatocellular carcinoma [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 89-95.
[5] LI Yanru, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Proteomic analysis of serum exosomes in pancreatic cancer with different stages of progress [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 33-41.
[6] HUA Fang, ZHANG Weiwei, LYU Bo, XIN Wei. Bioinformatic analysis of genes and molecular pathways associated with osteoarthritis synovitis [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 10-17.
[7] LI Canxuan, CHEN Jie. Expression and activity mechanism of acetyl-CoA acyltransferase 1 in clear cell renal cell carcinoma based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 26-33.
[8] WANG Yan, ZHANG Yuhui, HU Naibo, TENG Guangshuai, ZHOU Yuan, BAI Jie. Characteristics of bone marrow immune microenvironment in patients with acute myeloid leukemia based on single-cell RNA sequencing [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 32-40.
[9] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[10] SUN Yifeng, GAO Yu, LIANG Yongyuan, GAO Yang. Expression of CPLX2 and its in vitro effects on the proliferation migration and invasion of hepatocellular carcinoma cells [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 34-39.
[11] TIAN Baorui, ZHANG Yongchao, HAN Xiaoyang, TIAN Yingying, WANG Chuanxi. Prediction of the association between genes and glioblastoma based on databases [J]. Journal of Shandong University (Health Sciences), 2020, 58(6): 8-13.
[12] SHAO Qianqian, WANG Jingpu, WANG Qingjie. Expression and prognostic significance of apoptosis antagonizing transcription factor in hepatocellular carcinoma [J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 7-12.
[13] ZHOU Jian, ZHAO Hanting, LÜ Gang, WANG Lin, LI Qihang, ZHU Meiyan, WANG Zhilin, HE Shenyi. Bioinformatics analysis and construction of an eukaryocyte vector of ROP19 protein in Toxoplasma gondii [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 64-69.
[14] WANG Wei, CAO Yushan, SUN Daquan, HUANG Xiaoqiong, XU Guoqiang. Role of human TIMP-2 protein in the migration and invasion of hepatocellular carcinoma cell [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 11-17.
[15] YUE Qianqian, WANG Xinyi, YANG Zhiqiang, JIANG Shu. Quantitative analysis of spectral CT imaging on hypervascular hepatic metastasis and hepatocellular carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 50-55.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd